US Executive Compensation Proxy SEC Filings — October 19, 2026

19-10-2026

Lisata Therapeutics' DEF 14A proxy statement, dated October 19, 2026, covers board governance rather than financial performance. It includes the Audit Committee report (recommending that the audited FY2025 financial statements be included in the 2025 Form 10-K, with Grant Thornton LLP as independent auditor), the composition and responsibilities of the Compensation, Nominating and Governance, and Science and Technology committees, the use of Radford/AON as independent compensation consultant, director qualification and diversity considerations, nomination procedures, and stockholder communication channels. No revenue, earnings, or other quantitative financial results are disclosed in the excerpt.

• · Grant Thornton LLP is the independent registered public accounting firm for the fiscal year ended December 31, 2025, and the Audit Committee confirmed its independence.
• · Radford/AON has advised the Compensation Committee since March 2015 and was assessed as independent under SEC and Nasdaq rules.
• · Board nominees require majority approval of the full Board, including a majority of independent directors.
• · The Board has no formal diversity policy; it cites medicine, private equity, and pharmaceutical/healthcare management backgrounds among directors.
• · Stockholders may write to the Board via the Assistant Corporate Secretary at P.O. Box 173, Liberty Corner, NJ 07938, with communications distributed to all Board members.

19-10-2026

SR Bancorp, Inc. (SRBK), holding company for Somerset Regal Bank, filed its definitive proxy statement for the 2026 annual meeting of stockholders, to be held November 18, 2026 at 2:00 p.m. in Bridgewater, New Jersey. Stockholders will vote on electing three directors to three-year terms (Item 1) and ratifying Baker Tilly US, LLP as the independent registered public accounting firm for fiscal year ending June 30, 2027 (Item 2). As of the September 21, 2026 record date, 7,931,396 shares were outstanding, and the Board unanimously recommends voting FOR both proposals.

• · Internet voting deadline is 11:59 p.m. Eastern Time on November 17, 2026; ESOP and 401(k) Plan voting instruction deadline is November 11, 2026.
• · Director elections are by plurality; broker non-votes and withheld votes have no effect on the outcome, while the auditor ratification requires a majority of votes cast.
• · Three of nine directors (Orbach, Pribula, Taylor) are not independent because they are executive officers; the remaining six are independent under Nasdaq listing standards.
• · The Board has separated the Chairman and CEO roles, which it states enhances Board independence and oversight.
• · The Annual Report on Form 10-K covers audited financial statements for the fiscal year ended June 30, 2026.

19-10-2026

Beneficient (BENFW) has filed a DEF 14A proxy statement for a special meeting of stockholders on October 29, 2026, seeking approval under Nasdaq Listing Rule 5635(d) for issuing Class A Common Stock to Yorkville (YA II PN, Ltd.) under an amended and restated Standby Equity Purchase Agreement (A&R SEPA) and convertible promissory notes totaling $4.0 million original principal, which could exceed 20% of outstanding Common Stock. The Board recommends voting FOR both the Yorkville Share Issuance Proposal and the Adjournment Proposal; failure to approve would bar issuances above the Exchange Cap and constitute an amortization event accelerating amounts due under the notes. The filing also notes a prior 8-to-1 reverse stock split and Nasdaq compliance regained on January 2, 2026.

• · Failure to obtain stockholder approval would constitute an 'amortization event' accelerating amounts due under the Promissory Notes
• · Shares issued to Yorkville since June 26, 2026 are excluded from voting on the Yorkville proposal under Nasdaq Rule 5635(d)
• · Class B shares carry ten votes each, giving holders 1.6% of voting power despite 0.2% of equity
• · Proxy materials are being delivered in full-set format with the Special Meeting held at Haynes and Boone, LLP, Dallas, Texas
• · Record Date for stockholder voting is September 24, 2026; the meeting is scheduled for October 29, 2026 at 9:00 a.m. Central Time

19-10-2026

BioLargo, Inc. (BLGO) filed a definitive DEF 14A proxy statement for its 2026 Annual Meeting of Stockholders, to be held December 1, 2026 in Aliso Viejo, California. Stockholders will vote on electing seven directors, an advisory say-on-pay vote on named executive officer compensation, and ratification of Hacker Johnson & Smith PA as the independent auditor for fiscal 2026. The filing reports 334,661,950 common shares outstanding as of the October 15, 2026 record date, with no preferred shares outstanding.

• · Annual Meeting date and location: December 1, 2026 at 10:00 a.m. Pacific Time at Aliso Viejo Country Club, 33 Santa Barbara Drive, Aliso Viejo, CA 92656
• · Record date: October 15, 2026; Notice of Internet Availability of Proxy Materials to be mailed on or about October 21, 2026
• · Internet voting deadline: 11:59 p.m. Eastern Time on November 30, 2026
• · Board recommends voting FOR all seven director nominees, FOR the advisory say-on-pay proposal, and FOR auditor ratification
• · Annual Report on Form 10-K for fiscal year ended December 31, 2025 is included with the proxy materials
• · Company is a Delaware corporation headquartered at 14921 Chestnut St., Westminster, CA 92683
• · Payment of filing fee: no fee required

19-10-2026

Tesla's 2026 DEF 14A proxy statement highlights the company's governance approach, year-round shareholder engagement (70 investor visits, ~100 investor calls per quarter, 5 investor conferences in 2025), and board responsiveness. The 2025 management proposal to eliminate supermajority voting requirements failed to pass despite a 73.6% shareholder participation rate, with approximately 39.4% of outstanding shares in support; the Board has declined to repropose declassification or supermajority elimination at this time. Participation rose to approximately 74% at the 2025 Annual Meeting from 72% in 2024.

• · Board determined not to repropose binding declassification or supermajority elimination proposals at this time despite the 73.6% participation rate
• · Board amended pledging policy: CEO pledged stock loan cap set at lesser of $3.5B or 25% of pledged stock value; directors/officers (non-CEO) limit lowered from 25% to 15%
• · Corporate Governance Guidelines and Audit Committee Charter updated in 2025 to address Board and Audit Committee oversight of SI (super intelligence)
• · Voluntary retail voting program developed following an SEC staff no-action letter, aimed at increasing retail shareholder participation
• · Company claims one of the largest retail shareholder bases of any public company

19-10-2026

Synaptics Inc. (SYNA) stockholders are asked to approve a definitive all-cash merger agreement with onsemi under which each Synaptics share would receive $123.00 in cash, a stated 22% premium to the $100.79 closing price on September 29, 2026. The Synaptics board unanimously recommends a FOR vote, and the transaction is conditioned on stockholder adoption, with an outside date of June 25, 2027 (subject to up to three automatic three-month extensions). The board acknowledges that the notional value of the deal has fallen sharply with the broader semiconductor sell-off, and that Party A's competing stock-based proposal could carry a higher implied value, which the board judged less certain.

• · Merger Consideration is entirely cash, with no financing condition; onsemi has committed debt financing from Morgan Stanley Senior Funding, Inc.
• · Implied valuation multiples of 23.5x NTM Non-GAAP P/E and 4.5x NTM EV/revenue, above consumer and broad semiconductor peer medians and above selected transaction medians
• · Board concluded Party A's Revised Proposal, while possibly carrying higher implied notional value, faced stockholder approval risk, other conditionality, and risk of Party A share price correction
• · Outside date is June 25, 2027, with up to three automatic three-month extensions tied to antitrust and foreign direct investment conditions
• · Stockholder adoption of the Merger Agreement is a closing condition

19-10-2026

Summit Therapeutics' DEF 14A proxy seeks stockholder approval to increase authorized common stock from 1,000,000,000 to 2,000,000,000 shares, primarily to satisfy obligations under a September 28, 2026 private placement with AstraZeneca Holdings B.V. that raised $2.0B in gross proceeds through Class A Convertible Preferred Stock (closed October 5, 2026). The Board describes current unreserved authorized common shares (66,727,073 as of October 1, 2026) as inadequate, and warns that failure to approve could impair capital access and the company's ability to continue as a going concern. The filing also sets 2027 annual meeting deadlines for stockholder proposals and director nominations.

• · Charter Amendment must be effective by December 31, 2026 under the Purchase Agreement obligations
• · If the Required Increase Amendment is not effective by April 5, 2028 (Amendment Deadline), Summit must redeem all Class A Preferred Stock for cash at prevailing market value
• · Preferred stock conversion is also subject to HSR Act waiting period expiration, if applicable
• · Board states it may be unable to issue shares when needed and could face going-concern risk if the proposal fails
• · Stockholder proposals for the 2027 annual meeting are due by December 18, 2026; advance notice window runs February 10 to March 12, 2027; Rule 14a-19 universal proxy notice due by April 11, 2027
• · Authorized and unreserved common shares (66.7M) are insufficient to cover the 108.96M shares issuable on preferred conversion, so approval is needed before conversion can occur
• · Proposed increase would not itself be immediately dilutive, but future issuances could dilute EPS, book value, and voting power; existing holders have no preemptive rights

19-10-2026

Future FinTech Group Inc. (FTFT) filed a definitive DEF 14A proxy statement on October 19, 2026 for its Annual Meeting of Shareholders to be held November 19, 2026 in Hong Kong. Shareholders will vote on electing five directors, ratifying Wei, Wei & Co., LLP as auditor for FY2026, increasing authorized common stock from 9,375,000 to 900,000,000 shares, reducing the vote required to amend the Articles (Article IX, Section 1), and adopting a 2026 Omnibus Equity Plan. The company had 8,674,730 common shares outstanding as of the September 30, 2026 record date.

• · Authorized share increase would take authorized common stock from 9,375,000 to 900,000,000, roughly a 96-fold increase relative to current authorization, and would require approval by a majority of outstanding shares entitled to vote.
• · The Article 9.1 Amendment would lower the vote needed to amend the Articles from a majority of combined voting power of outstanding voting shares to a majority of votes cast at a meeting with a quorum present, a shareholder-rights change investors should review.
• · Directors are elected by plurality; abstentions and broker non-votes do not affect outcomes, and absent instructions proxies default to FOR all proposals.
• · Meeting is at the company's Hong Kong office (Causeway Bay), with proxy materials expected to be mailed on or about October 21, 2026.
• · The filing's cover page marks the filing as 'No fee required' and the document header references a FY2025 period, though the filing itself is a 2026 proxy.

19-10-2026

Turn Therapeutics Inc. (TTRX) filed its definitive DEF 14A proxy statement on October 19, 2026 for a virtual annual meeting of stockholders to be held November 30, 2026. Stockholders will vote on electing two Class I directors and ratifying WithumSmith+Brown, PC as the independent registered public accounting firm for fiscal 2026. The filing contains no financial results, performance comparisons, or regulatory actions.

• · Annual meeting held to satisfy Nasdaq Listing Rule 5620(a), which requires an annual meeting within one year after fiscal year-end
• · Internet and telephone voting close at 11:59 p.m. Eastern Time on November 29, 2026; mailed proxy cards must be received by the same deadline
• · Named executive officers are Bradley Burnam (CEO) and Zuraiz Chaudhary (Interim CFO), reflecting SEC smaller reporting company rules
• · Company is incorporated in Delaware, has fiscal year end December 31, and is headquartered in Westlake Village, California
• · Common Stock has par value $0.0001 per share; no cumulative voting rights and no appraisal or dissenters' rights apply to the proposals

19-10-2026

Aimei Health Technology Co., Ltd. (AFJKU) has filed a proxy statement for an Extraordinary General Meeting on November 10, 2026, seeking shareholder approval to extend its deadline to consummate a business combination from December 6, 2026 to December 6, 2027, along with an amendment to the trust agreement, ratification of MaloneBailey, LLP as auditor for 2026, and an adjournment proposal. If the Article Amendment Proposal is approved, public shareholders electing redemption will be able to redeem their Public Shares, meaning the extension carries redemption risk for the public float; the Board recommends voting FOR all proposals.

• · Public shareholders electing redemption will receive pro rata cash from the Trust Account if the Article Amendment Proposal passes; no redemption offer is made if it fails.
• · Directors, officers, the Sponsor, and affiliates are expected to vote in favor of all proposals, including any Public Shares they own, but cannot redeem Founder Shares or Private Units.
• · MaloneBailey, LLP has served as the Company's auditor since 2023; if shareholders reject the appointment, the Board and audit committee may reconsider the selection.
• · The Trust Agreement dated December 1, 2023 with Continental Stock Transfer & Trust Company is being amended to match the 48-month extension.
• · The Adjournment Proposal would allow the chairman to adjourn the meeting to solicit additional proxies if votes are insufficient.

19-10-2026

FTC Solar's definitive proxy statement, dated October 19, 2026, calls the 2026 Annual Meeting of Stockholders for November 30, 2026, held virtually. Stockholders will vote on electing three Class II directors, approving a share issuance to Lincoln Park Capital Fund (20% or more of outstanding common stock under an August 4, 2026 Purchase Agreement, for Nasdaq Rule 5635(d) purposes), and ratifying BDO USA, P.C. as auditor for fiscal 2026. The Board unanimously recommends voting FOR all proposals. The filing contains no financial results, so no period-over-period performance is reported.

• · Record date is October 7, 2026; the meeting is November 30, 2026 at 11:00 AM Central time.
• · Stock Issuance Proposal needs a majority of votes cast; abstentions and broker non-votes have no effect on it.
• · Auditor Ratification Proposal needs a majority of shares present and entitled to vote; abstentions count as votes against, and broker non-votes are not expected because the item is routine under Nasdaq rules.
• · The Director Election Proposal uses a plurality vote; withheld votes and broker non-votes do not count as votes cast.
• · Executive compensation, related-party transactions, and the equity compensation plan appear in the table of contents but are not in the excerpt provided.

19-10-2026

Crexendo, Inc. filed its DEF 14A proxy statement on October 19, 2026, seeking stockholder approval of an amendment to its 2021 Long-Term Incentive Plan that would add 5,000,000 shares for future grants, after the Board approved the amendment on October 3, 2026. The filing shows only 655,788 shares remained available under the 2021 Plan as of September 30, 2026, against approximately 3,646,753 shares subject to outstanding awards under prior plans, indicating limited equity-award capacity absent approval. The proxy also discloses a related-party consulting arrangement with Chairman Emeritus Steven G. Mihaylo that totaled only $168 for 2025 and has since ended.

• · Board approved the plan amendment on October 3, 2026, subject to stockholder approval
• · Stockholders are not required to approve plan repricing modifications; the plan lacks express prohibitions on discounted free-standing SARs, reload awards, and underwater cash buyouts
• · Change-in-control provisions automatically accelerate outstanding options/SARs and lapse restrictions on restricted stock/RSUs unless the award agreement provides otherwise; no excise-tax gross-ups
• · Annual equity grants typically occur the first day after the 10-K blackout period ends; milestone awards tied to material nonpublic information follow the post-release blackout
• · No compensation consultant was retained during fiscal 2025
• · Directors are reimbursed for travel and related expenses; non-employee director compensation is disclosed in the Form 10-K filed March 3, 2026

19-10-2026

Kochav Defense Acquisition Corp. (KCHVU), a Cayman Islands blank-check SPAC, has called an extraordinary general meeting for November 13, 2026 to seek shareholder approval for an Extension Amendment that would push its business combination deadline from November 29, 2026 to November 29, 2027, without any sponsor deposit into the trust. The Sponsor has advised it does not intend to make the $2,530,000 per three-month extension payments otherwise required. Redemption price is approximately $10.53 per public share versus a $10.50 Nasdaq close on October 16, 2026, with approximately $266.5 million in trust, and no definitive business combination agreement has been signed.

• · Public shareholders who do not redeem forgo up to $0.20 per share of trust funding contemplated by the existing governing documents
• · Non-redemption agreements would result in share issuances by the post-combination entity for no additional consideration, diluting non-participating public shareholders
• · If the extension fails and no business combination closes by November 29, 2026, the company will liquidate and redeem all public shares, with rights expiring worthless
• · Record date is October 13, 2026; approval of the Extension requires a two-thirds special resolution of votes cast
• · Board recommends voting FOR all three proposals

19-10-2026

Lantern Pharma's DEF 14A proxy statement, dated October 19, 2026, asks stockholders to elect six director nominees for one-year terms at the upcoming Annual Meeting. The Board is currently six members, five of whom are independent under NASDAQ and Rule 10A-3 standards, and it recommends a 'FOR' vote on all nominees. The excerpt contains no financial performance results for the period under review.

• · Board nominees: Keyser (Chairman, Audit and Compensation Committees), Sharma (CEO), Chandru, Maccecchini, Schalop, and Silberstein; each serves a one-year term
• · Panna Sharma has led the Company's use of AI and genomics in developing its precision oncology therapy pipeline
• · Lee T. Schalop joined the Board in July 2025 and is a former Chimerix Board Observer; Chimerix was sold to Jazz Pharmaceuticals in April 2025
• · The filing references the Company's 2025 Annual Report, filed with the SEC on March 30, 2026

19-10-2026

Patrick Industries, Inc. (PATK) and LCI Industries (LCII) have agreed under a June 30, 2026 merger agreement to combine in an all-stock transaction in which each LCI share converts into 1.2440 Patrick shares, valued at approximately $84.64 per LCI share as of October 16, 2026. Post-merger, Patrick shareholders are expected to own about 52% and LCI stockholders about 48% of the combined company, which will be renamed Patrick LCI, Inc. if the articles amendment is approved; both companies' special meetings are scheduled for November 18, 2026 (Patrick) and virtually for LCI. The filing is a definitive joint proxy statement/prospectus, and the merger is contingent on LCI stockholder approval and Patrick shareholder approval of the share issuance and authorized stock increase.

• · Patrick special meeting to be held virtually on November 18, 2026 at 10:00 a.m. ET; record date October 15, 2026
• · Patrick proposals: share issuance, authorized stock increase, articles amendment and restatement, and adjournment
• · LCI special meeting proposals: LCI merger adoption, non-binding advisory compensation on merger-related payments to named executive officers, and adjournment
• · Both boards unanimously recommend voting FOR their respective proposals
• · Merger completion requires LCI stockholder approval of the merger proposal and Patrick shareholder approval of both the share issuance and authorized stock increase proposals
• · Patrick common stock will remain listed on Nasdaq under PATK; LCI currently trades on NYSE under LCII
• · Filing references risk factors beginning on page 39 of the joint proxy statement/prospectus

19-10-2026

City National Rochdale Strategic Credit Fund has filed a definitive proxy statement for a special shareholder meeting on November 10, 2026, seeking approval for a new investment management agreement with American Beacon Advisors, Inc., a new sub-advisory agreement with CIFC Investment Management LLC, and the election of seven new trustees. The changes follow RBC Rochdale's stated wish to stop serving as investment adviser, with the aggregate advisory fee rate of 1.50% unchanged, but the pro forma expense ratio is expected to rise from 2.07% to 2.22%, partially offset by a three-year expense cap.

• · The Fund's name would change to American Beacon CIFC Strategic Credit Fund if the Adoption is completed.
• · RBC Rochdale portfolio managers Thomas Ehrlein and Charles Luke would leave the Fund's portfolio management team.
• · Proposals are interdependent: if any one is not approved, none take effect and RBC Rochdale and CIFC remain in place.
• · Asset Purchase Agreement between RBC Rochdale and American Beacon was signed May 13, 2026; Board approval was May 14, 2026.
• · Record date for voting is September 18, 2026; shareholders may vote by mail, telephone (1-800-690-6903), or internet (www.proxyvote.com).

19-10-2026

HeartSciences Inc. (HSCSW) filed a definitive proxy statement (DEFM14A) on October 19, 2026 in connection with a proposed combination with Fortitude, a Zcash and bitcoin mining business. The excerpt provided focuses on Fortitude's risk factors, including dependence on Zcash and bitcoin prices, a finite block reward that is halving over time, intensifying hash-rate competition with reduced Bitcoin hash-rate scaling, and rising power costs. The excerpt does not contain the transaction's consideration, exchange ratio, or vote timing, so those terms cannot be confirmed from this text.

• · Fortitude is shifting its strategic focus toward Zcash and other emerging proof-of-work ecosystems and is not prioritizing scaling its Bitcoin hash rate at the pace of overall network growth, which may reduce its share of Bitcoin rewards.
• · Fortitude reports difficulty procuring new miners on acceptable terms and accessing sufficient capital, which may constrain its hash-rate growth.
• · Power is a significant portion of Fortitude's cost base, and rising power prices, curtailments, or interconnection delays could materially reduce mining profitability.
• · Fortitude's strategy changes could bring added regulatory and compliance obligations, including licensing and permitting requirements.
• · Fortitude's cited data-center and high-power-site competition is tied to AI and high-performance computing demand for power.

19-10-2026

Onfolio Holdings Inc. (Nasdaq: ONFO) has filed a definitive proxy statement for a Special Meeting of Stockholders on November 5, 2026, seeking shareholder approval for a board-discretionary reverse stock split at a ratio of up to 1-for-250, plus an adjournment proposal in case votes are insufficient. The Board recommends voting FOR both proposals. As of the September 23, 2026 record date, 2,499,248 shares of common stock were outstanding.

• · Special Meeting to be held exclusively online on November 5, 2026 at 10:00 A.M. Eastern Time; pre-registration deadline is November 4, 2026 at 10:00 A.M. Eastern Time
• · Record date is September 23, 2026; the proxy materials were first mailed on or about October 19, 2026
• · Company states no dissenters' appraisal rights are available under DGCL, the Certificate of Incorporation, or Bylaws
• · Company expects no broker non-votes because both proposals are treated as routine matters
• · Board authority would allow it to select the split ratio in its sole discretion, up to 1-for-250, without returning to shareholders for a further split-ratio vote